Cancer Research KI list of cancer research PIs across KI, B
Please find the blood cancer, nervous system cancer researchers at KI listed in the tables below.
Note that this is an initial list that may still contain errors in part because the response rate on the conducted survey was below a hundred per cent. We would therefore like you to be in contact with us if you find that your name has been erroneously entered or if you would like to complete the current information in any way. Please send your update request to cancerresearchki@ki.se.
Contact details for the researchers can be found through the KI search function on the top right-hand side of this page.
Blood cancer research
| Surname | Given name | Department | Group website | Description |
|---|---|---|---|---|
| Achour | Adnane | MedS | https://ki.se/en/meds/research-group-adnane-achour-0 | MHC class I-restricted cancer-associated neoantigens and TEIPP. Design of altered peptide ligands through X-ray crystallography. |
| Alici | Evren | MedH | ||
| Bajalica Lagercrantz | Svetlana | Onk-Pat | ||
| Björkholm | Magnus | MedS | https://ki.se/meds/professor-magnus-bjorkholm | Biology of Hodgkin and related lymphomas. Epidemiology of hematological malignancies |
| Brodin | Petter | KBH | ||
| Bryceson | Yenan | MedH | ||
| Carlsten | Mattias | MedH | ||
| Chambers | Benedict | MedH | https://ki.se/en/medh/benedict-chambers-group | My research examines the role of innate immune cells in cancer. |
| Coquet | Jonathan | MTC | I study the role of the immune system in cancer elimination and growth. | |
| Ekström-Smedby | Karin | MedS | Risk, survival and survivorship of malignant lymphomas and other cancer forms | |
| Eloranta | Sandra | MEDS | https://ki.se/en/meds/kep-cancer-epidemiology-group | |
| Gabriel | Erin | MEB | ||
| Gerlach | Carmen | MedS | Our goal is to improve cancer immunotherapy (focus: adoptive T cell therapy & vaccination) by leveraging the unique functionalities of distinct T cell subsets | |
| Glimelius | Ingrid | MEDS | ||
| Grönlund | Hans | CNS | We do personal neoantigen predictions and tumor-specific T cell expansion and vaccination for clinical trials | |
| Hassan | Moustapha | LabMed | ||
| Hellström Lindberg | Eva | MedH | https://ki.se/en/medh/myelodysplastic-syndromes | improve cure rates and symptom-free survival for patients with myelodysplastic syndromes (MDS). |
| Henter | Jan-Inge | KBH | ||
| Höglund | Petter | MedH | ||
| Jacobsen | Sten Eirik | CMB | ||
| Kaipe | Helen | LabMed | https://ki.se/en/labmed/research-group-helen-kaipe | |
| Kallioniemi | Olli-Pekka | Onk-Pat | ||
| Karlsson | Anna | LabMed | ||
| Karlsson | Mikael | MTC | https://ki.se/en/mtc/mikael-karlsson-group | Immunotherapy targeting the cancer stroma with a foucus on Macrophages and B cells. |
| Kärre | Klas | MTC | ||
| Kiessling | Rolf | Onk-Pat | https://ki.se/onkpat/rolf-kiesslings-forskargrupp | Immunotherapy of cancer and studies of tumor immune escape. |
| Kimby | Eva | MedH | ||
| Lehmann | Soren | MedH | ||
| Lennartsson | Andreas | BioNut | https://ki.se/en/bionut/epigenetic-regulation-of-leukemia-and-normal-bl… | We are working on epigenomic and transcriptomic regulation, and epigenetic treatment of acute leukemia in adults and children. |
| Linder | Stig | Onk-Pat | ||
| Lindstrand | Anna | MMK | https://ki.se/mmk/sallsynta-diagnoser | Using zebrafish to develop combination therapies to overcome drug resistance in AML |
| Ljunggren | Hans-Gustaf | MedH | https://ki.se/en/medh/hans-gustaf-ljunggren-group | Cancer immunotherapy, in particular exploring the potential of using NK cells alone or in combination with other drugs in malignant diseases. Much of this is explored in Phase I or II clinical trials with extensive exploratory analysis of patient material following NK cell infusions. |
| Ljungman | Per | MedH | Viral infections and vaccinations after allogeneic stem cell transplantation mainly for malignancies. | |
| Luc | Sidinh | MedH | ||
| Lundin | Vanessa | MedH | ||
| Lundqvist | Andreas | Onk-Pat | https://ki.se/en/onkpat/andreas-lundqvists-group | Tumor Immunology, immunotherapy, tumor microenvironment |
| Malmberg | Karl-Johan | MedH | ||
| Månsson | Robert | Labmed | By linking genetics and epigenetics, we try to understand the aberrant gene regulatory mechanisms in multiple myeloma and chronic lymphocytic leukemia. | |
| Marquardt | Nicole | MedH | Our research includes a focus on NK cells in human lung cancer as well as in human sarcoma tumors. | |
| Marshall Heyman | Mats | KBH | ||
| Martinez Hoyer | Sergio | MTC | ||
| Masucci | Maria | CMB | mechanism of tumor virus immune regulation and oncogenesis | |
| Mattsson | Jonas | Onk-Pat | https://ki.se/en/onkpat/jonas-mattssons-group | Development of immunotherapy and CAR T-cell therapies in solid tumors with special focus on ovarian cancer |
| Mellstedt | Håkan | Onk-Pat | ||
| Michaelsson | Jakob | MedH | ||
| Mielke | Stephan | Labmed | ||
| Mjösberg | Jenny | MedH | https://ki.se/en/medh/jenny-mjosberg-group | We study immunological mechanisms in the airways and gut with focus on innate lymphoid cells. Our studies of inflammation and cancer are translational as they are performed using human tissues. |
| Nahi | Hareth | MedH | blood malignancy, multiple myeloma | |
| Nilsson | Gunnar | MedS | http://ki.se/en/meds/gunnar-nilsson-group | Primarily systemic mastocytosis, from QoL, to molecular mechanisms and regulation of mast cell hyoerreactivity. Secondly, mast cells as part of the tumor microenvironment. |
| Nilsson | Anna | KBH | https://medarbetare.ki.se/orgid/5206307 | Adaptive immunity in children with cancer. Effects of chemo on normal lymphocytes |
| Nordgren | Ann | MMK | ||
| Okret | Sam | BioNut | ||
| Palm Apergi | Caroline | LabMed | ||
| Palmblad | Jan | MedH | ||
| Pan Hammarström | Qiang | BioNut | https://ki.se/en/bionut/we-study-human-b-cells-in-health-and-disease-qi… | We study the mechanics involved in DNA repair and recombination during immunoglobulin gene diversification processes and their involvement in genome instability and cancer development. |
| Pokrovskaja | Katja | Onk-Pat | https://ki.se/en/onkpat/research-team-katja-pokrovskaja-tamm | Novel targeted therapies to overcome drug resistance in cancer treatment |
| Qian | Hong | MedH | ||
| Ringdén | Olle | ClinTec | ||
| Rosenquist Brandell | Richard | MMK | https://ki.se/mmk/klinisk-genetik | By applying multiple high-throughput technologies we explore the molecular landscape of clinically relevant subgroups of chronic lymphocytic leukemia (CLL). This approach will enhance our understanding of key molecular events in CLL ontogeny and tumor evolution, and enable us to identify novel prognostic, predictiveand therapy resistance biomarkers, as well as innovative drug targets tailored to well-definedpatient subgroups. |
| Sander | Birgitta | LabMed | ||
| Sarhan | Dhifaf | LabMed | Cancer immunotherapy- Exploiting innate memory and immune sexual dimorphism in the tumor microenvironment. | |
| Smith | Edvard | Labmed | ||
| Sönnerborg | Anders | MedH | ||
| Svensson | Mattias | MedH | ||
| Uhlin | Michael | ClinTec | ||
| Ungerstedt | Johanna | MedH | ||
| Vu | Nghia | MEB | ||
| Wahlin | Björn E. E. | MedH | ||
| Wermeling | Fredrik | MedS | https://www.cmm.ki.se/web/guest/fredrik-wermeling-team1 | CRISPR screens to identify how cancer cells resists immunotherapy in vivo. Also, projects related to how CRISPR enrich for mutations in tumor suppressor genes. |
| Westerberg | Lisa | MTC | https://ki.se/en/mtc/lisa-westerberg-group | Tumor Immunology and Cell biology |
| Woll | Petter | MedH | ||
| Wright | Anthony | LabMed | https://ki.se/labmed/forskargruppen-for-cancer-evolution | Understanding how missense mutations affecting the MYC and TP53 proteins promote cancer disease. Understanding lymphoma-related microenvironment interactions in relation to cancer cell survival and drug resistance. |
| Österborg | Anders | Onk-Pat |
Brain and nervous system, cancer research
| Surname | Given name | Department | Group website | Description | |
|---|---|---|---|---|---|
| Adameyko | Igor | FYFA | https://ki.se/en/fyfa/developmental-biology-and-regenerative-medicine | We do study neuroblastoma origin and heterogeneity | |
| Arenas | Ernest | MBB | |||
| Arsenian-Henriksson | Marie | MTC | |||
| Bartek | Jiri | MBB | |||
| Blomgren | Klas | KBH | Characterisation and prevention of cognitive and other late complications occurring after radiotherapy to the juvenile brain | ||
| Castelo-Branco | Goncalo | MBB | https://ki.se/en/mbb/goncalo-castelo-branco-group | We are currently investigating how oligodendrocyte precursor cells transition to glioma initiating cells and whether OPCs can transition to immunocompetent states in the context of glioma. | |
| Cheray | Mathilde | IMM | https://ki.se/en/imm/unit-of-toxicology | Epigenetic reprogramming in brain tumors and their microenvironment | |
| Ernfors | Patrik | MBB | |||
| Feychting | Maria | IMM | https://ki.se/en/imm/unit-of-epidemiology | Epidemiological studies mainly on brain tumors and childhood cancers. | |
| Frisén | Jonas | CMB | |||
| Harris | Robert | CNS | https://ki.se/en/cns/robert-harris-research-group | Novel immunotherapies for glioblastoma multiforme. Focus on myeloid cells, as therapeutic agents, in studies of microglia depletion,and using nanoparticles to deliver siRNA | |
| Hermanson | Ola | NEURO | https://ki.se/en/neuro/hermanson-laboratory | Molecular & bioengineering cues to steer and monitor stem-like cells in pediatric & adult neurooncology. | |
| Holmberg | Johan | CMB | https://ki.se/en/cmb/johan-holmbergs-group | Working on gene regulation and differentiation in neuroblastoma. | |
| Jardemark | Kent | FyFa | https://translationalpharmacology.com/ | Evaluation of antibodies against mutated KRAS in cancer cells | |
| Johnsen | John Inge | KBH | https://ki.se/kbh/neurala-barntumorer | Molecular and translational research on pediatric neural cancers | |
| Joseph | Bertrand | IMM | https://ki.se/en/imm/bertrand-joseph-research-group | Myeloid cells contribution to brain tumours. | |
| Kogner | Per | KBH | |||
| Muhr | Jonas | CMB | |||
| Nister | Monica | Onk-Pat | |||
| Shirazi Fard | Shahrzad | KBH | My research set out to investigate consequences of tumour heterogeneity for the progression into refractory disease, with the objective to target residual disease and prevent metastasis | ||
| Träger | Catarina | KBH | |||
| Wickström | Malin | KBH | New therapies in neuroblastoma | ||
| Wilhelm | Margareta | MTC | https://ki.se/en/mtc/margareta-wilhelm-group | Understanding the impact of tumor microenvironment on tumor development, and development of disease-relevant models for neural childhood malignancies | |
| Zaphiropoulos | Peter | BioNut | |||
| Ährlund-Richter | Lars | KBH |
Breast cancer research
| Surname | Given name | Department | Group website | Description |
|---|---|---|---|---|
| Andersson | Göran | LabMed | ||
| Barragan | Isabel | FyFa | https://ki.se/en/fyfa/pharmacoepigenetics | Omics and clinicopathological features integration to identify clinically relevant biomarkers of response to immunotherapy in cancer |
| Bergh | Jonas | Onk-Pat | ||
| Blaas | Leander | Bionut | We are studying breast development, breast cancer cells-of-origin, lineage plasticity,and tumor heterogeneity | |
| Czene | Kamila | MEB | Main focus of research is genetic and mammographic factors of breast cancer prognosis | |
| de Boniface | Jana | MMK | https://ki.se/mmk/forskning-brostkirurgi | 1. Large clinical cross-border prospective trials on the de-escalation of axillary surgery2. Prospective and retrospective research into breast reconstruction methods, their oncological safety and impact on quality of life3. Epidemiological studies on the impact of locoregional treatment on survival after breast cancer |
| Frisell | Jan | MMK | Clinical Breast cancer research | |
| Fuxe | Jonas | LabMed | https://ki.se/en/labmed/jonas-fuxe-group | We explore the interface between cancer and inflammation. In particular, we aim to elucidate how inflammatory signals contribute to cancer progression and metastasis by inducing epithelial-mesenchymal plasticity. |
| Gemzell Danielsson | Kristina | KBH | https://ki.se/en/kbh/reproductive-health | We are focusing on understanding the cause, identifying biomarkers for risk prediction and early diagnosis and the development of possible prophylactic treatment witha focus on gynecological cancer (including breast cancer, and women with brca mutations and endometriosis) |
| Hall | Per | MEB | ||
| Hartman | Johan | Onk-Pat | https://ki.se/en/onkpat/johan-hartmans-group | Pathology; prediction of drug response in cancer patients. AI and molecular assays |
| Humphreys | Keith | MEB | ||
| Kuskowska-Wolk | Alicja | IMM | ||
| Lendahl | Urban | CMB | https://ki.se/en/cmb/urban-lendahls-group | We work on the role of dysregulated Notch signaling in cancer. |
| Linderholm | Barbro | Onk-Pat | ||
| Lindström | Linda | Onk-Pat | https://ki.se/en/onkpat/linda-lindstroms-group | Given the diversity of breast cancer and that the biological factors influencing the risk to die from the disease are not well understood, the Lindström research group’s main scientific interest is to identify the tumor and host characteristics needed to enable us to predict a patient’s long-term risk for fatal disease. We work interdisciplinary and currently focus our research into understanding the impact of intratumor heterogeneity, factors important for the long-term risk, endocrine therapy benefit, young versus older age at diagnosis, and benign breast diseases. |
| Sandelin | Kerstin | MMK | ||
| Sangfelt | Olle | CMB | https://ki.se/en/cmb/olle-sangfelts-group | Our research focuses on studying the molecular mechanisms through which oncogenic ubiquitin ligasescontrols fundamental regulatory pathways and translate these basic research findings with the study of human cancer. |
| Spalding | Kirsty | CMB | https://ki.se/en/cmb/kirsty-spaldings-group | The contribution of human adipocytes to cancer progression and metastasis. |
| Strömblad | Staffan | BioNut | https://ki.se/en/bionut/cell-biology-of-cancer-staffan-stromblad-0 | Role of Cell-matrix interactions andCellular signaling in Cancer |
| Toftgård | Rune | BioNut | ||
| Wengström | Yvonne | NVS | https://ki.se/nvs/wengstrom-group | Exercise oncology, symptom improvement, screening behaviour |
| Wiedschwndter | Martin | KBH |